Abstracts tagged "Biologics"

Abstract Number: 2585 • 2018 ACR/ARHP Annual Meeting
Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
Atul A. Deodhar¹, Dafna D Gladman², Iain B. McInnes³, Vibeke Strand⁴, Mengyuan Ren⁵, Sebastian Spindeldreher⁶, Luminita Pricop⁷, Brian Porter⁷, Jorge Safi⁷, Abhijit Shete⁸ and Gerard Bruin⁶, ¹Oregon Health & Science University, Portland, OR, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals, Shanghai, China, ⁶Novartis Institutes for BioMedical Research, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody (mAb) that selectively targets IL-17A, is efficacious for the treatment of psoriasis, psoriatic arthritis (PsA) and ankylosing…
Abstract Number: 2955 • 2018 ACR/ARHP Annual Meeting
Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry
Lene Dreyer¹, Tine Iskov Kopp², Rikke Kart Jacobsen³, Melinda Magyari², Else Helene Ibfelt³, Henning Locht⁴, Finn Thorup Sellebjerg², Dorte Vendelbo Jensen⁵ and René Cordtz⁶, ¹Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ²Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁴Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ⁵The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Gentofte-Rigshospitalet, Hellerup, Denmark
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) have successfully been used for the treatment of immune-mediated inflammatory disorders including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…
Abstract Number: 1186 • 2018 ACR/ARHP Annual Meeting
Comparison of Biologic Discontinuation in Patients with Elderly-Onset Vs Younger-Onset Rheumatoid Arthritis
Michael Richter¹, Eric L. Matteson², John M. Davis III², Sara J. Achenbach³ and Cynthia S. Crowson³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Several studies have suggested that patients with elderly-onset rheumatoid arthritis (EORA) receive biologic treatments less frequently than patients with younger-onset RA (YORA). This has…
Abstract Number: 2206 • 2018 ACR/ARHP Annual Meeting
Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis
Scott Brunet^1,2,3, Sarah Manske^1,2,3, Klaus Engelke^4,5, Steven K. Boyd^1,2,3 and Cheryl Barnabe^2,6, ¹Biomedical Engineering, University of Calgary, Calgary, AB, Canada, ²McCaig Institute for Bone and Joint Health, Calgary, AB, Canada, ³Department of Radiology, University of Calgary, Calgary, AB, Canada, ⁴Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Medicine, Erlangen University Hospital, Erlangen, Germany, ⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Functional decline and reduced quality of life for patients with rheumatoid arthritis (RA) results from chronic changes to joints in patients, including bone erosions…
Abstract Number: 2591 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
Herman F Mann¹, Jakub Zavada², Lucie Nekvindová³, Zlatuse Kristkova³, Pavel Horák⁴, Jiri Vencovsky¹ and Karel Pavelka², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, ⁴IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with axial spondyloarthritis (AxSpA). This situation changed when anti-interleukin-17A…
Abstract Number: 11L • 2017 ACR/ARHP Annual Meeting
Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
Lene Dreyer¹, René Cordtz², Inger Marie J. Hansen³, Lars Erik Kristensen⁴, Merete Lund Hetland⁵ and Lene Mellemkjær⁶, ¹Center for Rheumatology and Spine Diseases, Gentofte University Hospital,Rigshospitalet, Hellerup, Denmark, ²Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Hellerup, Denmark, ³Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ⁴The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁵DANBIO, Glostrup Hospital.On behalf of all Depts of Rheumatology in Denmark.Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ⁶Danish Cancer Society Research Center, Copenhagen, Denmark, Copenhagen, Egypt

Background/Purpose: The safety of treatment with biological DMARDs (bDMARDs) has been carefully studied for the past 15 years, however, it is still largely unknown whether…
Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting
Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson^6,7 and Kimme L. Hyrich^1,6, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
Abstract Number: 637 • 2017 ACR/ARHP Annual Meeting
The Effect of Biologic Therapies on the Gut Microbial Composition in Psoriatic Arthritis
Julia Manasson¹, Carles Ubeda², Lu Yang³, Melania Fanok⁴, Gary E. Solomon¹, Soumya M. Reddy⁵, Sergei Koralov⁶, Jose C. Clemente⁷ and Jose U. Scher^1,4, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Institute for Research in Public Health, Valencia, Spain, ³New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ⁶Pathology, New York University School of Medicine, New York, NY, ⁷Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. If left untreated, it has the potential for significant morbidity and disability.…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
Abstract Number: 1966 • 2017 ACR/ARHP Annual Meeting
Risk of Tuberculosis in Biologic Users for Rheumatic Diseases: Results from the South African Biologics Registry
Clive Pettipher¹ and Romela Benitha², ¹Rheumatology, Private Practice, Stellenbosch, South Africa, ²Rheumatology, Private Practive, Johannesburg, South Africa
Background/Purpose: To evaluate the rate of tuberculosis (TB) in biologic users for rheumatic diseases in South Africa, a TB endemic country, the effectiveness of our…
Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Laura C Coates¹, Ana-Maria Orbai², Julie Birt³, Lisa Kerr³, Olivier Benichou³ and Philip S. Helliwell⁴, ¹University of Oxford, Leeds, Great Britain, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…
Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Michael D. George¹, Brian Sauer², Chia-Chen Teng, MS², Grant Cannon², Bryant R. England³, Gail S. Kerr⁴, Ted R. Mikuls⁵ and Joshua Baker⁶, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴VAMC, Georgetown University, Washington, DC, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
Abstract Number: 925 • 2017 ACR/ARHP Annual Meeting
Open-Source Conensus-Based Models to Improve the Cost-Effectiveness of Rheumatology Care
Devin Incerti¹, Jeffrey R. Curtis², Maria Lorenzi¹ and Jeroen Jansen¹, ¹Innovation and Value Initiative, Oakland, CA, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The treatment and prognosis of moderate to severe rheumatoid arthritis has improved considerably due to the advent of biological therapies. But at the same…
Abstract Number: 1464 • 2017 ACR/ARHP Annual Meeting
Relation of HLA-DRB1 Genotype to the Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis
Kensuke Oryoji, The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan
Background/Purpose: To investigate whether clinical efficacy of abatacept (ABT) and tocilizumab (TCZ) differs depending on whether or not HLA-DRB1 Shared Epitope (SE) is present in…

« Previous Page
1
…
6
7
8
9
10
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].